DelveInsight’s “Endometriosis Pipeline Insight 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Endometriosis pipeline landscape. It covers the Endometriosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Endometriosis Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Endometriosis Drugs @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight

Key Takeaways from the Endometriosis Pipeline Report

• On April 17, 2026- Gesynta Pharma AB initiated a clinical trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP). A Phase 2 study trial to Investigate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients With Moderate to Severe Endometriosis-related Pain – the NOVA Trial.
• DelveInsight’s Endometriosis Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline Endometriosis drugs.
• The leading Endometriosis Companies such as Gedeon Ritcher, Changchun GeneScience Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ferring Pharmaceuticals, Chugai Pharmaceutical, Foraviset, EpicentRx, NETRIS Pharma, Maipl Therapeutics, Flightpath Biosciences and others.
• Promising Endometriosis Therapies such as Triptorelin Embonate, Implantable gestrinone, KLH-2109, Oral Dienogest, Leuprorelin acetate, SN132D, OG-6219 and others.

Find out more about Endometriosis Drugs @ Endometriosis Treatment

Endometriosis Overview

Endometriosis is characterized by the growth of endometrial-like glands and stroma outside the uterus. These lesions may appear as peritoneal deposits, superficial ovarian implants or cysts, or as deep infiltrating disease. Although its exact cause remains unclear, several theories have been proposed to explain the development of endometriotic lesions. One widely discussed mechanism is retrograde menstruation, observed in women and certain non-human primates, where menstrual blood flows backward through the fallopian tubes into the pelvic cavity. This backward flow, together with possible spread via the blood or lymphatic system, can lead to the implantation of endometrial tissue in abnormal locations.

Endometriosis Emerging Drugs

• Estelle: Gedeon Ritcher

Estelle is Mithra’s first E4-based product, containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP). Estetrol, a natural estrogen produced by the human fetus during pregnancy, enters maternal circulation at relatively high levels. Its unique mechanism of action and favorable safety profile position Estetrol as a potential breakthrough in women’s health and other therapeutic areas. As the first native estrogen of fetal origin, E4 selectively targets estrogen receptors, a property expected to offer multiple benefits for patients. Currently the drug is in Phase III stage of its development for the treatment of Endometriosis.

• GenSci048: Changchun GeneScience Pharmaceutical Co., Ltd.

GenSci048, developed by Changchun GeneScience Pharmaceutical Co., Ltd., is an investigational subcutaneous therapy administered every four weeks for moderate to severe endometriosis-related pain. Currently entering Phase IIa, the agent is being evaluated for its effectiveness in alleviating dysmenorrhea and pelvic pain, along with its safety profile. The study is a randomized, double-blind, placebo-controlled trial, with primary outcomes assessing pain reduction on a numeric rating scale over 24 weeks. This development underscores GenSci’s commitment to advancing innovative solutions for women’s health and addressing unmet needs in gynecological care. Currently, the drug is in the Phase II stage of its development for the treatment of Endometriosis.

• NP137P: NETRIS Pharma

NP137P is a humanized IgG1 monoclonal antibody that targets netrin‑1, a key factor in epithelial-to-mesenchymal transition (EMT) and lesion progression. In preclinical endometriosis models, anti‑netrin‑1 treatment notably reduced lesion size and pain, establishing NP137P as the first non-hormonal, disease-modifying biologic candidate for this condition. The drug is currently being evaluated in Preclinical stage of its development for the treatment of Endometriosis.

The Endometriosis Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment.
• Endometriosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market.

Learn more about Endometriosis Drugs opportunities in our groundbreaking Endometriosis research and development projects @ Endometriosis Unmet Needs

Endometriosis Companies

Gedeon Ritcher, Changchun GeneScience Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ferring Pharmaceuticals, Chugai Pharmaceutical, Foraviset, EpicentRx, NETRIS Pharma, Maipl Therapeutics, Flightpath Biosciences and others.

Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we’re transforming the future of Respiratory Disease @ Endometriosis Market Drivers and Barriers, and Future Perspectives

Scope of the Endometriosis Pipeline Report

• Coverage- Global
• Endometriosis Companies- Gedeon Ritcher, Changchun GeneScience Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ferring Pharmaceuticals, Chugai Pharmaceutical, Foraviset, EpicentRx, NETRIS Pharma, Maipl Therapeutics, Flightpath Biosciences and others.
• Endometriosiss Therapies- Triptorelin Embonate, Implantable gestrinone, KLH-2109, Oral Dienogest, Leuprorelin acetate, SN132D, OG-6219 and others.
• Endometriosis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Endometriosis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for new Endometriosis Treatments, visit @ Endometriosis Drugs

Table of Contents

1. Introduction
2. Executive Summary
3. Endometriosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Endometriosis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Estelle: Gedeon Ritcher
9. Mid Stage Products (Phase II)
10. GenSci048: Changchun GeneScience Pharmaceutical Co., Ltd.
11. Early Stage Products (Phase I)
12. Preclinical and Discovery Stage Products
13. MP137P: NETRIS Pharma
14. Inactive Products
15. Endometriosis Key Companies
16. Endometriosis Key Products
17. Endometriosis- Unmet Needs
18. Endometriosis- Market Drivers and Barriers
19. Endometriosis- Future Perspectives and Conclusion
20. Endometriosis Analyst Views
21. Endometriosis Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/endometriosis-pipeline-insight